National Center for Microbiology, Instituto de Salud Carlos III, Majadahonda, 28220 Madrid, Spain.
National Center for Microbiology, Instituto de Salud Carlos III, Majadahonda, 28220 Madrid, Spain; Department of Science, Universidad Internacional de Valencia-VIU, 46002 Valencia, Spain.
Trends Microbiol. 2023 May;31(5):480-497. doi: 10.1016/j.tim.2022.12.003. Epub 2023 Jan 7.
Human cytomegalovirus (HCMV) is an important pathogen worldwide. Although HCMV infection is often asymptomatic in immunocompetent individuals, it can cause severe or even life-threatening symptoms in immunocompromised patients. Due to limitations of antiviral treatments, it is necessary to search for new therapeutic alternatives. Recent studies have highlighted the contribution of antibodies in protecting against HCMV disease, including neutralizing and non-neutralizing antibodies. Given the immunocompromised target population, monoclonal antibodies (mAbs) may represent an alternative to the clinical management of HCMV infection. In this context, we provide a synthesis of recent data revising the literature supporting and arguing about the role of the humoral immunity in controlling HCMV infection. Additionally, we review the state of the art in the development of therapies based on mAbs.
人巨细胞病毒（HCMV）是一种重要的病原体，在全球范围内广泛存在。虽然 HCMV 感染在免疫功能正常的个体中通常无症状，但它可导致免疫功能低下的患者出现严重甚至危及生命的症状。由于抗病毒治疗存在局限性，因此有必要寻找新的治疗替代方法。最近的研究强调了抗体在预防 HCMV 疾病中的作用，包括中和抗体和非中和抗体。鉴于免疫功能低下的目标人群，单克隆抗体（mAbs）可能是 HCMV 感染临床管理的一种替代方法。在此背景下，我们对支持和争论体液免疫在控制 HCMV 感染中的作用的最新文献进行了综述。此外，我们还回顾了基于 mAbs 的治疗方法的最新进展。
